Métodos diagnósticos no invasivos en cáncer pulmonar primario

Métodos diagnósticos no invasivos en cáncer pulmonar primario

Publicado 2018-09-01

Abrir | Descargar
PDF FLIP
Número
Vol. 20 Núm. 2 (2008)
Sección
Métodos diagnósticos en neumología
Cómo citar
Métodos diagnósticos no invasivos en cáncer pulmonar primario.
rev. colomb. neumol. [Internet]. 2018 Sep. 1 [cited 2024 Dec. 26];20(2):68-74.
DOI
Licencia
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Alirio Bastidas
Médico Internista - Residente II año Neumología, Hospital Militar Central. Bogotá, Colombia.
    Plutarco García Herreros
    Médico, Neumólogo Instituto Nacional de Cancerología – Universidad Nacional de Colombia. Bogotá, Colombia.
      Alfredo Saavedra
      Médico Internista – Neumólogo, Instituto Nacional de Cancerología – Universidad Nacional de Colombia. Bogotá, Colombia.
        Edgar Sánchez
        Médico Internista – Neumólogo, Instituto Nacional de Cancerología – Universidad Nacional de Colombia. Bogotá, Colombia.
          Mostrar biografía de los autores

          El cáncer pulmonar primario es un problema de salud pública a nivel mundial cuyo manejo genera grandes costos económicos en los sistemas de salud y donde su curación sólo se logra con un diagnóstico temprano asociado al manejo quirúrgico oportuno. En la búsqueda de este objetivo en la actualidad se dispone de varios métodos diagnósticos no invasivos entre los que se encuentra la citología de esputo, la radiografía de tórax, la tomografía axial computarizada y la tomografía con emisión de positrones. En el presente artículo, compuesto por dos partes, se discutirá con base a la literatura actual disponible la utilidad de estos métodos diagnósticos como herramientas de tamizaje, diagnóstico, estadiaje y seguimiento en este tipo de neoplasia.

          Visitas del artículo 92 | Visitas PDF 165

          Descargas

          Los datos de descarga todavía no están disponibles.
          1. Greenlee RT, Murria T, Bolden S, Wingo PA. Cancer statistics,2000. CA Cancer J Clin 2000; 50: 7-33.
          2. Jemal A, Siegel R, Ward E, Cancer statisties, 2007. CA Cancer J Clin 2007; 57: 43-66.
          3. Instituto Nacional de Cancerología, Incidencia estimada por cáncer en Colombia 1995-1999, Impresión 2005.
          4. Instituto Nacional de Cancerología, Anuario Estadístico 2006,Volumen 4; Impresión Noviembre 2007.
          5. Piñeros M, Murilo RH. Incidencia de cáncer en Colombia Importancia de las Fuentes de Información en la Obtención de Cifras Estimadas, Revista Colombiana de Cancerologia 8(1):5-14.
          6. Shopland DR, Eyre HJ, Pechacek TF. Smoking attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 1991; 83: 1142-1148.
          7. Jernal A, Tiwari RC, Murria T. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
          8. Lee P, Forey B. Why are lung cancer rate trends so different in the United States and United Kingdom? Inhalation Toxicology 2003; 15: 909-949.
          9. Flehinger BJ, Kimmel M, Nelamed MR. The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest 1992; 101: 1013-1018.
          10. Henschke CI, Wisnivesky JP, Yankelevitz DF, Miettinen OS. Small stage I cancers of the lung: genuineness and curability.Lung Cancer 2003; 39: 327-330.
          11. Brett GZ. Earlier diagnosis and survival in lung cancer. BMJ 1969; 4: 260–2. Artinian V, Kvale P. Update in screening of lung cancer, Respirology 2005; 10: 558-566.
          12. Hulka BS. Cancer screening. Degress of proof and practical application. Cancer 1988; 62: 1776-1780.
          13. Black WC, Welch HG. Screening for disese. Am J Roentgenol 1997; 168: 3-11.
          14. Clark R, Reingtgen D. Principles of screening. In: Reigtge D, Clark R. Cancer Screening. St. Louis, MO: Mosby; 1996. p. 1-20.
          15. US Departament of Health and Human Services (US DHHS).National Lung Cancer Screening Trial – What is the appropriate measure of screening effectiveness? Disponible en: http://www.cancer.gov/nlst/what-is-nlst.
          16. Rosa UW, Prolla JC, Gastal ES. Cytology in diagnosis of cancer affecting the lung. Result in 1000 consecutive patients. Chest 1973; 63: 203-207.
          17. Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography. An update for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140: 740–53.
          18. Kennedy TC, Proudfoot SP, Piantadosi S, et al. Efficacy of two sputum collection techniques in patients with air flor obstruction. Acta Cytol 1999; 43: 630-636.
          19. Johnson FL, Donohue JF, Shaffer CL. Improved sputum expectoration following a single dose of INS316 in patients with chronic bronchitis. Chest 2002; 122: 2021-2029.
          20. Murria K, Dubai E, Salter D, Monaghan H. Efficacy and pattern of use of sputum cytology as a diagnostic test. Cytopathology 2002; 13: 350-354.
          21. Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996; 201: 798-802.
          22. Frost JK, Ball WC, Levin ML, et al. Early lung cancer detection:results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins Study. Am Rev Respir Dis 1984;130:549–54.
          23. Flehinger BJ, Melamed MR, Zaman MB, Heelan RT, Perchick WB, Martini N. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering Study.Am Rev Respir Dis 1984;130:555–60.
          24. Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic Study. Am Rev Respir Dis 1984; 130: 561–5.
          25. Melamed MR, Flehinger BJ, Zaman MB. Screening for early lung cancer: results of the Memorial Sloan-Kettering Study in New York. Chest 1984; 86: 44–53.
          26. Tuckman MS. Survival and mortality from lung cancer in a screened population: the Johns Hopkins study. Chest 1986; 89: 325S–6S.
          27. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: the Mayo Program. J Occup Med 1986;28:746–50.
          28. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended followup. J Natl Cancer Inst 2000; 92: 1308–16.
          29. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36: 453–71.
          30. Kubik A, Polak J. Lung cancer detection results of a randomized prospective study in zechoslovakia. Cancer 1986;57: 2427–37.
          31. Wilde J. A 10 year follow-up of semi-annual screening for early detection of lung cancer in the Erfurt County, GDR. Eur Respir J 1989;2:656–62.
          32. Bach PB, Kelley MJ, Tate RC, McCrory DC. Screening for lung cancer: a review of the current literature. Chest 2003; 123:72S–82S.
          33. Hirsch FR, Prindiville SA, Byers T, et al. Sputum cytology as a marker of risk for lung cancer—preliminary results from the University of Colorado high-risk cohort study. Proc Am Soc Clin Oncol 2002;21(301a) [abstract 1201].
          34. Saccomanno G, Saunders RP, Archer VE, et al. Cancer of the lung: the cytology of sputum prior to the development of carcinoma. Acta Cytol 1965;9:413-423.
          35. Saccomanno G, Archer VE, Auerbach O, et al. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 1974; 33: 256-270.
          36. Risse EK, Vooijs GP, van’t Hof MA. Diagnostic significance of «severe dysplasia» in sputum cytology. Acta Cytol 1988; 32: 629-634.
          37. Prindiville SA, Byers T, Hirsch FR, et al. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev 2003; 12: 987-993.
          38. McWilliams A, Lam S. The utilization of autofluorescence in flexible bronchoscopy. In: Wang KP, Mehta AC, Turner JF, eds. Flexible Bronchoscopy, 2nd ed. Boston: Blackwell Science, 2004. p. 138-145.
          39. Hirsch FR, Prindiville SA, Miller YE, et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst 2001; 93: 13851391.
          40. Sato M, Sakurada A, Sagawa M, et al. Diagnostic results before and after introduction of autofluorescence bronchoscopy in patients suspected of having lung cancer detected by sputum cytology in lung cancer mass screening. Lung Cancer 2001; 32: 247-253.
          41. Moro-Sibilot D, Jeanmart M, Lantuejoul S, et al. Cigarette smoking, preinvasive bronchial lesions, and autofluorescence bronchoscopy. Chest 2002; 122: 1902-1908.
          42. Tockman MS, Gupta PK, Myers JD, et al. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J Clin Oncol 1988; 6: 1685-1693.
          43. Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of preclinical lung cancer: results from the studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 1997; 3: 2237-46.
          44. Mao L, Hruban RH, Boyle JO, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54: 1634-1637.
          45. Yakubovskaya MS, Spiegelman V, Luo FC, et al. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer 1995; 63: 810-814.
          46. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997;89:857-862.
          47. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997; 89: 1366-1373.
          48. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991; 253: 49-53.
          49. Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999; 91: 332-9.
          50. Andriani F, Conte D, Mastrangelo T, et al. Detecting lung cancer in plasma with the use of multiple genetic markers. Int J Cancer 2004;108:91-6.
          51. Wistuba II, Berhens C, Virmani AK, et al. Allelic losses at chromosome 8p21–23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 1999; 59: 1973-9.
          52. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-692.
          53. Tsou J, Hagen J, Carpenter C, Offringa L, DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002; 21: 5450-5461.
          54. Sozzi G, Conte D, Leon M, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003;21:3902–8.
          55. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1:61-67.
          56. Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-255.
          57. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Heman JG. Detection of aberrant promoter hypermethylation of tumour suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67–70.
          58. Valle RP, Chavany C, Zhukov TA, Jendoubi M. New approaches for biomarker discovery in lung cancer. Expert Rev Mol Diagn 2003; 3: 55–67.
          59. Tockman MS, Erozan YS, Gupta P, et al. The early detection of second primary lung cancers by sputum immunostaining. LCEWDG Investigators. Lung Cancer Early Detection Group. Chest 1994; 106(6 Suppl): 385S-390S.
          60. Wang Y, Hsu HS, Chen TP, Chen JT, Molecular diagnostic Markers for Lung Cancer in Sputum and Plasma. Ann N Y Acad Sci 2006; 1075: 179-184.
          61. Payne PW, Sebo TJ, Doudkine A, et al. Sputum screening by quantitative microscopy: a reexamination of a portion of the National Cancer Institute Cooperative Early Lung Cancer Study. Mayo Clin Proc 1997; 72: 697-704.
          62. Palcic B, Garner DM, Beveridge J, et al. Increase of sensitivity of sputum cytology using high-resolution image cytometry: field study results. Cytometry 2002;50:168-176.
          63. McWilliams A, Mayo J, McDonal S, et al. An Alternative Approach to Lung Cancer Sreening. Oral Sessions/Signaling and Pathways, S41.
          64. Xing S, Khanavkar B, Nakhosteen JA, Atay Z, Jöckel K, Marek W, Predictive Value of Image Cytometry for Diagnosis of Lung Cancer in Heavy Smokers. Eur Resp J 2005; (25)6: 956-963.
          65. Collins L, Haines C, Perkel R, Enck R, Lung Cancer: Diagnosis and Management. Am Fam Phys 2007; 75 (1): 57-63.
          66. Checani V. Bronchoscopic diagnosis of solitary pulmonary nodules and lung masses in the absence of endobronchial abnormality. Chest 1996; 109: 620-625.
          67. Mehta AC, Kathawalla SA, Chan CC, Arroliga A. Role of bronchoscopy in the evaluation of solitary pulmonary nodule.J Bronchoscopy 1995; 2: 315-321.
          68. Cortese DA, McDougall JC. Biopsy and brushing of peripheral lung cancer with fluoroscopic guidance. Chest 1979; 75: 141-145.
          69. Wallace JM, Deutsch AL. Flexible fiberoptic bronchoscopy and percutaneous needle lung aspiration for evaluating the solitary pulmonary nodule. Chest 1982; 81: 665-671.
          70. Stringfield JT, Markowitz DJ, Bentz RR, et al. The effect of tumor size and location on diagnosis by fiberoptic bronchoscopy. Chest 1977; 72: 474-476.
          71. Pirozynski M. Bronchoalveolar lavage in the diagnosis of peripheral lung cancer. Chest 1992; 102: 372–374.
          72. Shiner RJ, Rosenman J, Katz I, et al. A bronchoscopic evaluation of peripheral lung tumors. Thorax 1988; 43: 867–889.
          73. Wang KP, Haponik EF, James Britt E, et al. Transbronchial needle aspiration of peripheral pulmonary nodules. Chest 1984;86: 819–823.
          74. Raab SS, Hornberger J, Raffin T. The importance of sputum cytology in the diagnosis of lung cancer: a cost-effective analysis. Chest 1997; 112(4): 937–945.
          75. Passero M. Techniques for the Diagnosis of Lung Cancer.Cancer of the Lung: From Molecular Biology to Treatment Guidelines. 2002. Chapter 5. p 135.
          76. Brett GZ. The value of lung cancer detection by six-monthly chest radiographs. Thorax 1968;23:414–20.
          77. Brett GZ. Earlier diagnosis and survival in lung cancer. BMJ 1969;4:260–2.
          78. Fontana RS, Sanderson DR, Woolner LB. Lung cancer screening: the Mayo Lung cancer program. J Occup Med 1986;28: 746-750.
          79. Tockman MS. Lung cancer screening: The Johns Hopkins Study 1986; 89 (suppl): 324.
          80. Melamed MR, Flehinger BJ, Zaman MB. Screning for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984; 86: 44-53.
          81. Gohagan JK, Prorok PC, Hayes RB, The Prostate. Lung,Colorectal and Ovarian (PLCO) Cancer Screening Trial of the Nacional Cancer Institute: history, organization, and status. Control Clin Trials 2000; 21(suppl 6): 251S-272S.
          82. Gomersall L, Olson S. Imaging in lung cancer. Imaging 2004;16:1.
          83. Goldmeir E. Limits of visibility of bronchogenic carcinoma. Am Rev Respir Dis 1965; 91: 232.
          84. Theros E. Vatying manifestations of peripheral pulmonary neoplasms: a radiologic-pathologic correlative study. Am JRoentgenol 1977; 128: 893.
          85. Kundel HL. Predictive value and threshold detectability of lung tumors. Radiology 1981; 139: 25.
          86. Muhm JR, Miller WE, Fontana RS, Sanderson DR, Uhlenhopp MA, Lung cancer detected during a screening program using four-month chest radiographs. Radiology 1983; 148: 609.
          87. Woodring J. Pitfalls in the radiologic diagnosis of lung cancer. Am J Roentgenol 1990; 154:609.
          88. Good C, Wilson T. The solitary circumscribed pulmonary nodule. JAMA 1958; 166:210.
          89. Yankelevitz D, Henschke C. Does 2-year stability imply pulmonary nodules are benign? Am J Roentgenol 1997; 168:325.
          90. Patz EF, Jr. Imaging bronchogenic carcinoma. Chest 2000;117: 90, 23.
          Tutoriales

          Autores:

          ¿Cómo enviar un artículo?

          Par evaluador:

          ¿Cómo evaluar un artículo?

          Información

          Historia de la revista

          Palabras clave

          Directorios e indexadores

           

          Patrocinadores

           Nos apoyan + Info Aquí 

          Perfil de Google Scholar

          Más leídos en los últimos 30 días

          Número actual

          Código QR

          Sistema OJS 3.4.0.7 - Metabiblioteca |